PDCD1 and head and neck squamous cell carcinoma: Recently, the introduction of ICIs, particularly those targeting the programmed cell death protein 1 (PD-1)/programmed cell death ligand 1 (PD-L1) axis, has improved survival in patients with recurrent or metastatic (R/M) HNSCC.